Alexandra Arias-Mendoza

TL;DR: Among patients with heart failure and a reduced ejection, patients who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo.

TL;DR: Serelaxin is a recombinant form of human relaxin-2, a vasodilator hormone that contributes to cardiovascular and renal adaptations during pregnancy as discussed by the authors, but it is not suitable for pregnant women.

TL;DR: Only the new-onset AF that developed during the CCU stay in patients with NSTE-ACS was associated with a 4.40-fold increase in the in-hospital mortality risk, and the presence of any type of AF was not associated with an increased risk of mortality.

TL;DR: The baseline characteristics of participants in GALACTIC‐HF are described and how these compare with other contemporary trials are described.

TL;DR: Incorporation of LUS into clinical follow-up of patients with HF significantly reduced the risk of urgent visits for worsening HF and no significant differences in rehospitalizations for HF or death were found.